Safety and Efficacy of the Noncessation Method of Antithrombotic Agents after Emergency Endoscopic Hemostasis in Patients with Nonvariceal Upper Gastrointestinal Bleeding: A Multicenter Pilot Study
Table 4
Characteristics of patients before and after propensity score matching in groups A and B.
Before propensity score matching
Group A
Group B
value
Standardized differences
Number of patients (N)
43
154
Age (years)
77.8 ± 9.1
72.8 ± 12.4
0.004
0.47
Gender, male
28 (65.1%)
108 (70.1%)
0.58
0.11
Helicobacter pylori infection
20 (46.5%)
107 (69.5%)
0.007
0.48
Number of antithrombotics, multiple
11 (25.6%)
38 (24.7%)
1.00
0.02
Antiplatelet agents
30 (69.8%)
133 (86.4%)
0.02
0.41
Anticoagulant agents
17 (39.5%)
33 (21.4%)
0.03
0.40
Location of ulcer, gastric
34 (79.1%)
108 (84.4%)
1.00
0.14
Number of ulcers, single
28 (65.1%)
80 (62.5%)
0.86
0.05
Size of ulcer, >11 mm
21 (48.8%)
83 (64.8%)
0.07
0.33
After propensity score matching
Group A
Group B
value
Standardized differences
Number of patients (N)
40
40
Age (years)
77.1 ± 8.9
78.2 ± 8.0
0.55
0.13
Gender, male
26 (65.0%)
24 (60.0%)
0.82
0.10
Helicobacter pylori infection
19 (47, 5%)
20 (50.0%)
1.00
0.05
Number of antithrombotics, multiple
11 (27.5%)
12 (30.0%)
1.00
0.05
Antiplatelet agents
30 (75.0%)
31 (77.5%)
1.00
0.06
Anticoagulant agents
14 (35.0%)
12 (30.0%)
0.81
0.11
Location of ulcer, gastric
33 (82.5%)
36 (90.0%)
0.52
0.22
Number of ulcers, single
26 (65.0%)
26 (65.0%)
1.00
0.00
Size of ulcer, >11 mm
21 (52.5%)
22 (55.0%)
1.00
0.05
Group A: patients taking antithrombotic agents who underwent emergency endoscopic hemostasis for nonvariceal upper gastrointestinal bleeding and resumed antithrombotic medication without a cessation period; group B: patients taking antithrombotic agents who underwent emergency endoscopic hemostasis for nonvariceal upper gastrointestinal bleeding for whom antithrombotic medication was transiently discontinued.
